← Eichor
Study identifier: NCT07491497 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Condition: ALK-positive NSCLC · ALK-Positive Lung Cancer · ALK-positive Non-small Cell Lung Cancer  ·  Sponsor: TRIANA Biomedicines, Inc.

PhasePhase 1/Phase 2
Planned participants160
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication

This description comes directly from the study's public registry record.

Talk to the study team

TRIANA Clinical Trials  ·  medical@trianabio.com

Always discuss trial participation with your own doctor first.

Locations (12)

UCSFSan Francisco, California, United StatesRecruiting
University of Colorado Cancer CenterAurora, Colorado, United StatesRecruiting
Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting
Dana Farber Cancer CenterBoston, Massachusetts, United StatesRecruiting
Washington University Medical CenterSt Louis, Missouri, United StatesRecruiting
Memorial Sloan-Kettering Cancer CenterNew York, New York, United StatesRecruiting
Duke UniversityDurham, North Carolina, United StatesRecruiting
Taylor Cancer Research CenterMaumee, Ohio, United StatesRecruiting
SCRI Oncology PartnersNashville, Tennessee, United StatesRecruiting
Oncology Consultants Research (P1 Trials)Houston, Texas, United StatesRecruiting
START Mountain RegionWest Valley City, Utah, United StatesRecruiting
NEXT VirginiaFairfax, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07491497